Lobaplatin

The treatment strategy for previously standard treated non-small cell lung cancer (NSCLC) still remains challenged. This study was to evaluate the effectiveness and safety of epirubicin-loaded drug-eluting bead transbronchial artery chemoembolization (D-BACE) plus bronchial artery infusion chemotherapy (BAIC) in patients with refractory advanced NSCLC.

Between January 2018 and December 2022, 32 patients with refractory advanced NSCLC [26 males; mean age of 64±9.3 (range, 41-78) years; 19 squamous carcinomas (59.4%)] who had received one or more previous standard treatments and received D-BACE (epirubicin 50 mg) plus BAIC (lobaplatin 30 mg/m²) were included in our study. The study evaluated several parameters including local tumor response based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, progression-free survival (PFS), overall survival (OS), and complication rates. To examine the impact of different factors on PFS and OS, Kaplan-Meier and Cox regression analyses were performed.

A total of 68 D-BACE plus BAIC sessions (median, 1, range 1-7) were performed. Overall response and disease control rates were 25% and 100%, respectively. The median PFS and median OS were 6.0 months [95% confidence interval (CI): 4.1-7.9] and 14.0 months (95% CI: 4.8-23.2), respectively. The number of cycles in the D-BACE plus BAIC treatment was found to be an independent predictor of PFS and OS. There were no instances of severe procedure-related complications or deaths during the study.

The combination of D-BACE and BAIC shows great potential as a treatment choice for patients with refractory advanced NSCLC.

Transarterial chemoembolization (TACE) utilizing a water‐in‐oil lipiodol emulsion is a preferable therapeutic strategy for advanced liver cancer in clinical practice. However, the low stability of the lipiodol emulsion and poor efficacy of chemotherapeutic drug seriously undermine the efficiency of TACE. Herein, a novel lobaplatin‐loaded lipiodol emulsion (denoted as ICN‐LPE) is developed by constructing a lipiodol Pickering emulsion (LPE) stabilized with iron‐doped carbon nanozymes (ICN) to mitigate the issue of lipiodol‐water separation. This novel emulsion not only solves the instability of conventional lipiodol emulsions, but also facilitates the sustained release of lobaplatin. More importantly, upon entry into tumor cells, ICN catalyze the generation of reactive oxygen species via the Fenton‐like reaction while simultaneously consuming intracellular glutathione, thereby inducing tumor cell death via chemodynamic therapy. By integrating chemotherapy and chemodynamic therapy, ICN‐LPE demonstrates a synergistic antitumor effect and effectively inhibits tumor growth in a rabbit liver tumor model. Therefore, our ICN‐LPE shows an appealing clinical application prospect for TACE.